BNBX logo

BNB PLUS CORP

BNBXNASDAQ
๐Ÿ† #4192 by market capUS Equity
$0.16โ–ฒ $0.00 (+0.00%)
Market closed ยท at close
1hโ€”
24hโ–ฒ 0.0%
7dโ–ฒ 3.2%
14dโ–ฒ 3.2%
30dโ–ฒ 3.2%
1yโ–ผ 96.1%
๐ŸฆMarket Cap
$210,492
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
-37.7%
Declining
๐Ÿ“ŠGross Margin
43.5%
Healthy
๐Ÿ’ตFCF Margin
-659.2%
Thin
โš–๏ธP/S Ratio
0.1x
Cheap
Otter Score
61
Fair

Trading Snapshot

Day Range
$0.16 โ€“ $0.16
52-Week Range
$0.11 โ€“ $7.15
Volume
$2.66B
Avg Volume
$1.96B
Shares Outstanding
1.3M
Next Earnings
Aug 31, 2026

Fundamentals Snapshot

Annual Revenue
$2M
Last Q Revenue
$1M
P/E Ratio
-0.0
P/S Ratio
0.1x
EPS (TTM)
$-3.54
Dividend Yield
0.00%

Why Investors Own BNBX

  • โœ“High-growth profile โ€” revenue up -9.7% YoY with expanding US Equity exposure.
  • โœ“Healthy economics โ€” 47% gross margin and 17% free-cash-flow margin.
  • โœ“New products and segments could unlock additional revenue streams.
โš ๏ธ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$2Mโ–ผ โˆ’14.0% YoY
Gross Margin (TTM)
47.3%โ–ฒ +3.5% YoY
Operating Income (TTM)
$670,998โ–ผ โˆ’14.0% YoY
Free Cash Flow (TTM)
$367,553โ–ผ โˆ’14.0% YoY

About BNB PLUS CORP

BNB Plus Corp., established in 1983 and based in Stony Brook, NY, is a biotechnology firm dedicated to pioneering and commercializing technologies for the synthesis and identification of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company's operations are divided into three distinct business segments. Its Therapeutic DNA Production Services division specializes in the enzymatic manufacturing of synthetic DNA, used in the creation of nucleic acid-based treatments, and also develops and markets its proprietary RNA Polymerase (RNAP) for mRNA therapeutic production. The MDx Testing Services segment concentrates on developing clinical molecular diagnostic and genetic assessments, in addition to providing comprehensive clinical laboratory testing services. Lastly, the DNA Tagging and Security Products and Services segment leverages DNA detection techniques for securing industrial supply chains and offering various security solutions.

๐Ÿฆฆ

Otter Score Breakdown

โ“˜
๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Fair
61/100

Analyst Ratings

โ“˜
Consensus
Sell
6 analysts
Strong Buy0
Buy0
Hold3
Sell1
Strong Sell2
Ratings as of Jan 2026

Latest News & Updates